| Name | Title | Contact Details |
|---|
The Storch-Murphy Group is a Englewood, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Carenet Health is a leading provider of healthcare consumer engagement solutions, clinical support, health advocacy and navigation solutions, and 24/7 access to medical care. Our engagement specialists, care coordinators and registered nurses support 1 in 4 Americans (more than 86 million healthcare consumers) on behalf of 250+ of the nation`s premier health plans, providers, health systems and Fortune 500 organizations. Our mission is to drive market-leading consumer engagement outcomes through our proprietary Intelligent Engagement model. Our best-practice solutions are delivered by outstanding teams and backed by clinical capital, data and technology, operational excellence and expertise from outside of healthcare. Every day, our team members guide people to high-quality and cost-effective care, and coach them to close gaps in care and improve their health. For eight consecutive years, Inc. Magazine named Carenet as one of America`s fastest-growing private companies.
Pro-Dex, Inc. is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiSorb Systems, Inc. is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.